Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

Trial Profile

A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2019

At a glance

  • Drugs Peginterferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Acronyms ATTAIN
  • Sponsors Biogen
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 19 Jun 2018 Results of subgroup analysis of ADVANCE/ATTAIN presented at the 4th Congress of the European Academy of Neurology
    • 27 Apr 2018 Results of a subgroup analysis from ADVANCE, ATTAIN, TEMSO and TOWER studies comparing the clinical outcomes of peginterferon beta-1a and teriflunomide in DMT niave RMS patients, presented at the 70th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top